CoChat

Peptide‐based multi‐agonists: a new paradigm in metabolic pharmacology

Open access
Brandt, S. J., Müller, T. D., DiMarchi, R. D., Tschöp, M. H., Stemmer, K. · 2018 · Journal of Internal Medicine
Cited by 65

The DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index.

Abstract

Obesity and its comorbidities, such as type 2 diabetes, are pressing worldwide health concerns. Available anti‐obesity treatments include weight loss pharmacotherapies and bariatric surgery. Whilst surgical interventions typically result in significant and sustained weight loss, available pharmacotherapies are far less effective, typically decreasing body weight by no more than 5–10%. An emerging class of multi‐agonist drugs may eventually bridge this gap. This new class of specially tailored drugs hybridizes the amino acid sequences of key metabolic hormones into one single entity with enhanced potency and sustained action. Successful examples of this strategy include multi‐agonist drugs targeting the receptors for glucagon‐like peptide‐1 (GLP‐1), glucagon and the glucose‐dependent insulinotropic polypeptide (GIP). Due to the simultaneous activity at several metabolically relevant receptors, these multi‐agonists offer improved body weight loss and glucose tolerance relative to their constituent monotherapies. Further advancing this concept, chimeras were generated that covalently link nuclear acting hormones such as oestrogen, thyroid hormone (T 3) or dexamethasone to peptide hormones such as GLP‐1 or glucagon. The benefit of this strategy is to restrict the nuclear hormone action exclusively to cells expressing the peptide hormone receptor, thereby maximizing combinatorial metabolic efficacy of both drug constituents in the target cells whilst preventing the nuclear hormone cargo from entering and acting on cells devoid of the peptide hormone receptor, in which the nuclear hormone might have unwanted effects. Many of these multi‐agonists are in preclinical and clinical development and may represent new and effective tools in the fight against obesity and its comorbidities.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/joim.12837

Cites

82 of 82 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 82 references

Cited by

See all 65

Metadata

Authors
Brandt, S. J., Müller, T. D., DiMarchi, R. D., Tschöp, M. H., & Stemmer, K.
Venue
Journal of Internal Medicine
Publisher
Wiley
Published
2018-10-23
Volume
284
Issue
6
Pages
581-602
ISSN
  • 0954-6820 (ISSN-L)
  • 1365-2796
OpenAlex
W2891323571
Cited by
65
References
82
FWCI
3.52
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Peptide‐based multi‐agonists: a new paradigm in metabolic pharmacology. https://app.cochat.ai/papers/10.1111/joim.12837
The paper
Brandt, S. J., Müller, T. D., DiMarchi, R. D., Tschöp, M. H., & Stemmer, K. (2018). Peptide‐based multi‐agonists: a new paradigm in metabolic pharmacology. Journal of Internal Medicine. https://doi.org/10.1111/joim.12837

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.